For Immediate Release  
July 19, 2012

SUNSHINE BIOPHARMA ENGAGES BETA PHARMA CANADA FOR MANUFACTURING OF AN INITIAL BATCH OF Adva-27a

Montreal, Quebec, Canada -- (Marketwire) -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai (China). Beta Pharma Canada Inc., headquartered in Montreal (Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).

“We are delighted to be working with Beta Pharma Canada with excellent in-house synthesis capability and can amass additional resources through its corporate affiliations”, said Dr. Steve N. Sillaty, Sunshine’s President and CEO. “We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month”, he added.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:  
Camille Sebaaly, CFO  
Sunshine Biopharma Inc.  
Direct Line: 514-814-0464  
camille.sebaaly@sunshinebiopharma.com  
www.sunshinebiopharma.com